Vimarsana
Biggest News Aggregation in the World

Page 3 - Slate Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Slate Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Slate Development Today - Breaking & Trending Today

CPhI and Pharma Intelligence announce 2022 editions of Pharma IPR India and Biopharma Conclave in Mumbai - Vimarsana News

CPhI and Pharma Intelligence announce 2022 editions of Pharma IPR India and Biopharma Conclave in Mumbai

Published: September 14, 2022

Mumbai (Maharashtra) [India], September 14 (ANI/Newsvoir): Pharma Intelligence, now Citeline, one of the leading business intelligence providers and knowledge partners, is pleased to announce the 11th Pharma IPR India 2022, and the 4th edition of Biopharma Conclave 2022 organised by the Informa Markets division of Informa PLC. Biopharma Conclave 2022 will take place on September 15 and 16 at Aster, the St. Regis Mumbai, and Pharma IPR India 2022 is set convene from September 14th to 16th, 2022 at Imperial, the St. Regis Hotel, Mumbai. These comprehensive conclaves will be synchronised, and whi...

Source: laosnews.net
Related Topics:
New DelhiIndian BiosimilarsPoornachandra TejasviBiocon BiologicsSlate DevelopmentKnowledge PartnershipInnovation Novel TechnologySyngene InternationalViatris IncRegis HotelResearch DevelopmentPharma IntelligenceBiopharma ConclaveInforma MarketsRegis MumbaiChina Pharma DesignUnited KingdomBio InnovatorsEvolving Patent LandscapeDissecting Trade SecretsNovel TechnologyClinical TrialsPatent FrameworkPfizer IndiaReliance Lifesciences
Trendy Blackstone District developer looks to build $22 million project in North Omaha - Vimarsana News

Trendy Blackstone District developer looks to build $22 million project in North Omaha

Published: September 7, 2022

OMAHA — A midtown real estate team best known for turning a forsaken urban corridor into the trendy Blackstone commercial district is venturing into different territory. GreenSlate Development wants to

Source: fremonttribune.com
Related Topics:
City Of OmahaUnited StatesEppley AirfieldSaddle CreekUniversity Of Nebraska Medical CenterDennis SciscoeJustin WayneLozier Cindy GonzalezClay VanderheidenTerrell MckinneyJay LundMatt DwyerCushman Wakefield Lund CoCourtesy Of Omaha Planning DepartmentMfj EnterprisesGreenslate DevelopmentNebraska ExaminerSlate DevelopmentStorz ExpresswayNinth StreetOmaha Planning DepartmentSarpy CountyNorth OmahaAmerican Rescue Plan ActFarnam Street
U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

Published: August 25, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...

Source: prnewswire.com
Related Topics:
Craig TendlerChristie CorbettSusan StewartJanssen ResearchJanssen Biotech IncJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonTranslational SciencesDiagnostics Medical AffairsGlobal Head Of Late DevelopmentNational Comprehensive Cancer NetworkNone Of The Janssen Pharmaceutical CompaniesNational CenterDrug AdministrationExchange CommissionHematology Oncology Janssen Research DevelopmentCompanies Of JohnsonSeattle ChildrenExecutive DirectorConfidence IntervalGlobal HeadSlate DevelopmentMedical AffairsOncology Janssen Research
The Janssen Pharmaceutical Companies - U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease - Vimarsana News

The Janssen Pharmaceutical Companies - U.S. FDA Approves IMBRUVICA (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

Published: August 25, 2022

HORSHAM, PA - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has approved IMBRUVICA for the treatment of pediatric patients one... | August 25, 2022

Source: marketscreener.com
Related Topics:
Craig TendlerChristie CorbettSusan StewartJanssen ResearchNone Of The Janssen Pharmaceutical CompaniesSlate DevelopmentJanssen Biotech IncDrug AdministrationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesExchange CommissionDiagnostics Medical AffairsHematology Oncology Janssen Research DevelopmentNational Comprehensive Cancer NetworkExecutive DirectorConfidence IntervalGlobal HeadMedical AffairsOncology Janssen ResearchPharmaceutical CompaniesInfectious DiseasesPrivate Securities Litigation Reform ActAnnual ReportQuarterly ReportNews Publishing
Janssen: European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL) - Vimarsana News

Janssen: European Commission Approves IMBRUVICA (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Published: August 4, 2022

Approval marks the first all-oral, once-daily, fixed-duration Bruton's tyrosine kinase (BTK) inhibitor-based regimen for first-line treatment of CLL The Janssen Pharmaceutical Companies of Johnson

Source: finanznachrichten.de
Related Topics:
United StatesNoord HollandCraig TendlerJenni MildonEdmond ChanArnon KaterHematology Am Soc Hematol Educ ProgramJanssen Biotech IncEuropean Hematology AssociationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyDiagnostics Medical AffairsGlobal Head Of Late DevelopmentAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesAmsterdam University Medical CentresUniversity Of AmsterdamEuropean CommissionWorld Health OrganisationExchange CommissionCompanies Of JohnsonArea Lead HaematologyDeputy Head